- Home
- BBCP vs ADCT Comparison
BBCP vs ADCT Comparison
Compare BBCP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBCP
- ADCT
- Stock Information
- Founded
- BBCP 1983
- ADCT 2011
- Country
- BBCP United States
- ADCT Switzerland
- Employees
- BBCP N/A
- ADCT N/A
- Industry
- BBCP Engineering & Construction
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- BBCP Consumer Discretionary
- ADCT Health Care
- Exchange
- BBCP Nasdaq
- ADCT Nasdaq
- Market Cap
- BBCP 363.9M
- ADCT 398.2M
- IPO Year
- BBCP 2017
- ADCT 2020
- Fundamental
- Price
- BBCP $7.04
- ADCT $3.26
- Analyst Decision
- BBCP Buy
- ADCT Strong Buy
- Analyst Count
- BBCP 2
- ADCT 6
- Target Price
- BBCP $7.50
- ADCT $7.80
- AVG Volume (30 Days)
- BBCP 93.9K
- ADCT 545.2K
- Earning Date
- BBCP 09-04-2025
- ADCT 11-06-2025
- Dividend Yield
- BBCP N/A
- ADCT N/A
- EPS Growth
- BBCP N/A
- ADCT N/A
- EPS
- BBCP 0.16
- ADCT N/A
- Revenue
- BBCP $395,562,000.00
- ADCT $77,246,000.00
- Revenue This Year
- BBCP N/A
- ADCT $13.10
- Revenue Next Year
- BBCP $1.28
- ADCT $6.23
- P/E Ratio
- BBCP $44.33
- ADCT N/A
- Revenue Growth
- BBCP N/A
- ADCT 15.73
- 52 Week Low
- BBCP $4.78
- ADCT $1.05
- 52 Week High
- BBCP $9.68
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- BBCP 50.05
- ADCT 52.13
- Support Level
- BBCP $6.97
- ADCT $3.15
- Resistance Level
- BBCP $7.30
- ADCT $3.38
- Average True Range (ATR)
- BBCP 0.27
- ADCT 0.17
- MACD
- BBCP -0.00
- ADCT -0.01
- Stochastic Oscillator
- BBCP 30.91
- ADCT 39.45
About BBCP Concrete Pumping Holdings Inc.
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators position it to deliver concrete placement solutions. The company's operating segment includes U.S. Concrete Pumping; U.K. Operations; U.S. Concrete Waste Management Services and Corporate. It generates maximum revenue from the U.S. Concrete Pumping segment. Geographically, it generates majority of the revenue from its business in United States.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).